BeiGene's PD-1 drug approved in EU for first-line oesophageal cancer treatment
The European Commission has approved Tevimbra (tislelizumab) in combination with chemotherapy as a first-line treatment for oesophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma.